Interim Report 2026
Filed with HKEX · Stock code 6887 · · 142 pages · English and Chinese
2 Financial Highlights 3 Corporate Profile 7 Management Discussion and Analysis 75 Corporate Governance and Other Information 91 Review Report 93 Consolidated Statement of Profit or Loss and Other Comprehensive Income 95 Consolidated Statement of Financial Position 97 Consolidated Statement of Changes in Equity 99 Consolidated Cash Flow Statement 101 Notes to the Unaudited Interim Financial Report
Sunshine Lake Pharma Co., Ltd. on 6ix
Earlier from Sunshine Lake Pharma
- Next Day Disclosure Return
- Inside information filing with the CSRC in relation to the proposed implementation of h share full circulation
- Lannett Company, Lanexa Biologics and Sunshine Lake Pharma announce FDA Approval of LANGLARA™ an Interchangeable Biosimilar of Lantus® (insulin glargine)
- Sunshine Lake Pharma Co., Ltd. (06887.HK) Completes Listing, Market Capitalisation Expected to Rapidly Surpass RMB 50 Billion
Later from Sunshine Lake Pharma
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement Insulin Degludec and Insulin Aspart Injection obtained marketing approval from the china national medical products administration
- Change of company secretary, authorized representative and process agent
Follow Sunshine Lake Pharma into a list and get an email when it puts out news.
Follow Sunshine Lake Pharma